DK3157548T3 - Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom - Google Patents
Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom Download PDFInfo
- Publication number
- DK3157548T3 DK3157548T3 DK15741128.1T DK15741128T DK3157548T3 DK 3157548 T3 DK3157548 T3 DK 3157548T3 DK 15741128 T DK15741128 T DK 15741128T DK 3157548 T3 DK3157548 T3 DK 3157548T3
- Authority
- DK
- Denmark
- Prior art keywords
- factor xii
- therapy use
- xii inhibitor
- neurotraumatic disease
- neurotraumatic
- Prior art date
Links
- 229940123835 Factor XII inhibitor Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14172910 | 2014-06-18 | ||
| PCT/EP2015/063760 WO2015193457A1 (en) | 2014-06-18 | 2015-06-18 | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3157548T3 true DK3157548T3 (da) | 2021-09-06 |
Family
ID=50972542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15741128.1T DK3157548T3 (da) | 2014-06-18 | 2015-06-18 | Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20170114119A1 (enExample) |
| EP (1) | EP3157548B1 (enExample) |
| JP (1) | JP7109160B2 (enExample) |
| KR (1) | KR102513050B1 (enExample) |
| CN (1) | CN106456778A (enExample) |
| AU (1) | AU2015276089B2 (enExample) |
| BR (1) | BR112016029624A2 (enExample) |
| CA (1) | CA2950988C (enExample) |
| DK (1) | DK3157548T3 (enExample) |
| ES (1) | ES2886859T3 (enExample) |
| PL (1) | PL3157548T3 (enExample) |
| WO (1) | WO2015193457A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3157548T3 (pl) | 2014-06-18 | 2022-01-17 | Csl Behring Gmbh | Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym |
| WO2017171594A1 (en) * | 2016-03-30 | 2017-10-05 | Tadeusz Wieloch | Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages. |
| CN109071629A (zh) * | 2016-04-06 | 2018-12-21 | 杰特有限公司 | 治疗动脉粥样硬化的方法 |
| CN111479587B (zh) | 2017-12-15 | 2024-01-09 | 杰特有限公司 | FXIIa抑制剂在治疗肾纤维化和/或慢性肾脏疾病中的应用 |
| US12134657B2 (en) * | 2018-11-28 | 2024-11-05 | Oregon Health & Science University | Therapeutic factor XII antibody |
| EP4333901A4 (en) * | 2021-05-03 | 2025-07-09 | Harvard College | FC FUSION PROTEIN-BASED THERAPEUTIC AGENT FOR THE TREATMENT OF PANCREATITIS |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| WO1991017258A1 (en) | 1990-05-10 | 1991-11-14 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
| WO1996018412A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU2001264563A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1572936A2 (en) | 2002-03-05 | 2005-09-14 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| ATE440619T1 (de) | 2003-05-06 | 2009-09-15 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor-fc chimere proteine zur behandlung von hämophilie |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| JP4629047B2 (ja) | 2003-06-12 | 2011-02-09 | イーライ リリー アンド カンパニー | Ｇｌｐ−１アナログ複合タンパク質 |
| CA2537273A1 (en) | 2003-09-05 | 2005-03-17 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
| KR20060124656A (ko) | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질 |
| AU2005318464B2 (en) | 2004-12-23 | 2012-02-23 | Csl Behring Gmbh | Prevention of thrombus formation and/or stabilization |
| CA2678001C (en) | 2007-02-12 | 2017-07-11 | Stefan Schulte | Therapeutic application of kazal-type serine protease inhibitors |
| WO2011069090A1 (en) * | 2009-12-04 | 2011-06-09 | Alavita Pharmaceuticals, Inc. | Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine |
| US20120156230A1 (en) | 2010-12-17 | 2012-06-21 | Abbot Stewart | Treatment of spinal cord injury and traumatic brain injury using placental stem cells |
| CA2829037C (en) | 2011-03-09 | 2022-05-17 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| RU2660370C2 (ru) | 2011-07-22 | 2018-07-05 | Цсл Беринг Гмбх | Ингибирующие моноклональные антитела против фактора xii/xiia и их применения |
| EP2548892A1 (en) * | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| US10471142B2 (en) | 2011-09-24 | 2019-11-12 | Csl Behring Gmbh | Combination therapy using immunoglobulin and C1-Inhibitor |
| EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| ES2844189T3 (es) | 2013-03-08 | 2021-07-21 | Csl Behring Gmbh | Tratamiento y prevención de lesiones remotas por isquemia-reperfusión |
| EP3013366B1 (en) | 2013-06-28 | 2021-08-25 | CSL Behring GmbH | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
| US9587903B2 (en) | 2014-02-24 | 2017-03-07 | Brian E. Sullivan | Pneumatic launcher system and method |
| PL3157548T3 (pl) | 2014-06-18 | 2022-01-17 | Csl Behring Gmbh | Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym |
| CN109071629A (zh) | 2016-04-06 | 2018-12-21 | 杰特有限公司 | 治疗动脉粥样硬化的方法 |
-
2015
- 2015-06-18 PL PL15741128T patent/PL3157548T3/pl unknown
- 2015-06-18 BR BR112016029624A patent/BR112016029624A2/pt not_active Application Discontinuation
- 2015-06-18 CA CA2950988A patent/CA2950988C/en active Active
- 2015-06-18 US US15/318,550 patent/US20170114119A1/en not_active Abandoned
- 2015-06-18 KR KR1020177001620A patent/KR102513050B1/ko active Active
- 2015-06-18 DK DK15741128.1T patent/DK3157548T3/da active
- 2015-06-18 JP JP2016573808A patent/JP7109160B2/ja active Active
- 2015-06-18 ES ES15741128T patent/ES2886859T3/es active Active
- 2015-06-18 EP EP15741128.1A patent/EP3157548B1/en active Active
- 2015-06-18 WO PCT/EP2015/063760 patent/WO2015193457A1/en not_active Ceased
- 2015-06-18 AU AU2015276089A patent/AU2015276089B2/en active Active
- 2015-06-18 CN CN201580032338.8A patent/CN106456778A/zh active Pending
-
2019
- 2019-10-29 US US16/666,886 patent/US12065481B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2886859T3 (es) | 2021-12-21 |
| AU2015276089B2 (en) | 2021-03-18 |
| EP3157548A1 (en) | 2017-04-26 |
| EP3157548B1 (en) | 2021-08-04 |
| PL3157548T3 (pl) | 2022-01-17 |
| US20170114119A1 (en) | 2017-04-27 |
| US12065481B2 (en) | 2024-08-20 |
| CN106456778A (zh) | 2017-02-22 |
| BR112016029624A2 (pt) | 2017-10-24 |
| US20200131248A1 (en) | 2020-04-30 |
| CA2950988C (en) | 2024-02-06 |
| WO2015193457A1 (en) | 2015-12-23 |
| KR102513050B1 (ko) | 2023-03-29 |
| AU2015276089A1 (en) | 2017-02-02 |
| JP7109160B2 (ja) | 2022-07-29 |
| JP2017524675A (ja) | 2017-08-31 |
| CA2950988A1 (en) | 2015-12-23 |
| KR20170016503A (ko) | 2017-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2025038I1 (no) | Risdiplam or a pharmaceutically acceptable salt thereof - forlenget | |
| NO2022046I1 (no) | Berotralstat and pharmaceutically acceptable salts thereof | |
| NO2022009I1 (no) | Lumasiran, optionally in the form of a salt | |
| NO2022058I1 (no) | Capmatinib or a pharmaceutically acceptable salt thereof | |
| DK3140310T3 (da) | Syntese af boronatsalte og brug deraf | |
| MA41117A (fr) | Imagerie d'un corps | |
| LT3092017T (lt) | Vienkartinio naudojimo vienkartinio rinkinio jungtis | |
| DK3228254T3 (da) | Sæt omfattende et kirurgisk instrument | |
| DK3219089T3 (da) | Træning i afgivelse af et lægemiddel | |
| ME03325B (me) | Inhibitor aurora a kinaze | |
| DK3193805T3 (da) | En bærbar kørestol med dobbelt konfiguration | |
| DK3224471T3 (da) | Spil | |
| DK3151814T3 (da) | Behandling af en hudlæsion | |
| LT3212237T (lt) | Metotreksato vaistinė forma | |
| DK3157548T3 (da) | Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom | |
| HUE055779T2 (hu) | Amantadin a járás javítására szklerózis multiplexben | |
| HUE062326T2 (hu) | Fokozott stabilitású gyógyászati készítmény | |
| DK3125874T3 (da) | Et terapeutisk middel til anvendelse i behandlingen af infektioner | |
| EP3215049C0 (en) | ARTIFICIAL TEETH | |
| FI20135069L (fi) | Puukappaleen uusi käyttö | |
| HUE046209T2 (hu) | Kompozíció porckoronggal összefüggõ fájdalom kezelésében történõ alkalmazásra | |
| DK3105485T3 (da) | Tilvejebringelse af et forudbestemt fluid | |
| FR3026994B1 (fr) | Glissiere non deformable en cas d'accident | |
| NO20141516A1 (no) | Plaster | |
| FI20145661A7 (fi) | Gravitaatioestimaatin muodostus |